<div class="container">

<table style="width: 100%;"><tr>
<td>ReturnOCS</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>Gives operating characteristics of phase 123 and conventional design.</h2>

<h3>Description</h3>

<p>Returns the probability of selecting the optimal dose, type I error, generalized power, probability of making the best decision, average number of patients treated and average trial duration.
</p>


<h3>Usage</h3>

<pre><code class="language-R">ReturnOCS(Results, Means, CMu, Delta, Hyp)
</code></pre>


<h3>Arguments</h3>

<table>
<tr style="vertical-align: top;">
<td><code>Results</code></td>
<td>
<p>List containing phase 123 and conventional design results.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>Means</code></td>
<td>
<p>True mean survival times for experimental agents at each dose.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>CMu</code></td>
<td>
<p>Mean survival time for the control therapy.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>Delta</code></td>
<td>
<p>Desired improvement in survival.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>Hyp</code></td>
<td>
<p>Null=0 or alternative=1 hypthesis</p>
</td>
</tr>
</table>
<h3>References</h3>

<p>[1] Chapple and Thall (2018). A Hybrid Phase 12/3 Clinical Trial Design Allowing Dose-Re-Optimization in Phase 3 Biometrics. Under Review.
</p>


<h3>Examples</h3>

<pre><code class="language-R">##True Mean Control
CMu=24
##True Means Agent
Means = c(27,32,38,42,28)
##Desired improvement in mean survival
Delta=12
##Random Trial results
 Results=as.list(c(0,0))
 nSims=5
 X=matrix(rep(NA,nSims*4),nrow=nSims)
 ##DoseSelected
 X[,1]=c(2,3,4,4,3)
 X[,2]=c(0,1,1,1,1)
 X[,3]=c(270,500,500,420,400)
 X[,4]=c(70,85,88,70,88)
 Results[[1]]=X
 X[,1]=c(2,3,5,4,2)
 X[,2]=c(0,1,0,1,0)
 X[,3]=c(270,500,450,420,415)
 X[,4]=c(70,82,80,70,79)
Results[[2]]=X
Hyp=1
ReturnOCS(Results,Means,CMu,Delta,Hyp)
</code></pre>


</div>